These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26465402)

  • 1. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?
    Godoy DA; Rabinstein A
    Arq Neuropsiquiatr; 2015 Oct; 73(10):848-51. PubMed ID: 26465402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method.
    Kesici S; Tanyıldız M; Yetimakman F; Bayrakci B
    J Child Neurol; 2019 Apr; 34(5):277-283. PubMed ID: 30696330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS).
    Shalman A; Savir S; Mechnik Steen Y; Ovanyan A; Boniel N; Koyfman L; Bichovsky Y; Zlotnik A; Klein M; Brotfain E
    J Clin Neurosci; 2020 Apr; 74():247-249. PubMed ID: 32088107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
    Verma R; Chaudhari TS; Raut TP; Garg RK
    J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
    Ortiz-Corredor F; Peña-Preciado M
    Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous immunoglobulin and plasmapheresis on nerve conduction parameters compared to the natural course of Guillain-Barré syndrome.
    Kalita J; Mahajan R; Kumar M
    J Clin Neurosci; 2024 Jul; 125():76-82. PubMed ID: 38759351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
    Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
    BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An elderly case of Guillain-Barré syndrome with anti-GT1b antibodies].
    Kinboshi M; Morimoto Y; Yoshida T; Kuzume D; Yamasaki M
    Rinsho Shinkeigaku; 2019 Sep; 59(9):600-603. PubMed ID: 31474642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome (demyelinating) six weeks after bariatric surgery: A case report and literature review.
    Ishaque N; Khealani BA; Shariff AH; Wasay M
    Obes Res Clin Pract; 2015; 9(4):416-9. PubMed ID: 25765350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile of Guillain Barre syndrome.
    Dhadke SV; Dhadke VN; Bangar SS; Korade MB
    J Assoc Physicians India; 2013 Mar; 61(3):168-72. PubMed ID: 24475678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.